DZ BANK/PUT/GILEAD SCIENCES/65/0.1/20.06.25

DZ BANK/PUT/GILEAD SCIENCES/65/0.1/20.06.25 Stock

DE000DQ2CG29

Market Closed - Boerse Frankfurt Warrants 15:34:39 2024-07-12 EDT
0.45 ^EUR	-4.26%

Current month	-13.46%
1 month	-35.71%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart DZ BANK/PUT/GILEAD SCIENCES/65/0.1/20.06.25

Latest news about GILEAD SCIENCES, INC.

Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78	07-11	MT
New HIV Drug Can Only Offer Hope of Ending Aids If All Have Access, UNAIDS Says	07-11	AQ
RBC Cuts Price Target on Gilead Sciences to $71 From $74, Keeps Sector Perform Rating	07-09	MT
Raymond James Upgrades Gilead Sciences to Outperform From Market Perform, Price Target is $93	07-08	MT

More news

Quotes 5-day view

Date	Price	Change
24-07-12	0.45	-4.26%
24-07-11	0.47	-6.00%
24-07-10	0.5	-3.85%
24-07-09	0.52	-3.70%
24-07-08	0.54	-5.26%

Real-time Boerse Frankfurt Warrants

Last update July 12, 2024 at 03:34 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	GILEAD SCIENCES, INC.
Issuer	DZ BANK
WKN	DQ2CG2
ISIN	DE000DQ2CG29
Date issued	2024-04-05
Strike	65 $
Maturity	2025-06-20 (341 Days)
Parity	10 : 1
Emission price	0.37 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.79 €
Lowest since issue	0.43 €
Spread	0.01 €
Spread %	2.13%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company